GB2578271A - Method and apparatus for designing a course of treatment - Google Patents
Method and apparatus for designing a course of treatment Download PDFInfo
- Publication number
- GB2578271A GB2578271A GB1811060.1A GB201811060A GB2578271A GB 2578271 A GB2578271 A GB 2578271A GB 201811060 A GB201811060 A GB 201811060A GB 2578271 A GB2578271 A GB 2578271A
- Authority
- GB
- United Kingdom
- Prior art keywords
- physiological parameter
- data
- time
- cohort
- sub
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Aggregated data is used to identify cyclic variations in physiological parameters which variations may be associated with an adverse medical condition or event. The timing of these variations in the population (or particular demographic sub-cohorts of that population) can then be used to determine the timing and/or dosage level for the administration of medicaments associated with reducing the deviation in the physiological parameter concerned. The method may account for irregularities in the sampling of data associated with normal patient care by aggregating data from large numbers of patients, perhaps from a large number of medical facilities such as hospitals. Demographic ranges and vector calculations over daily, weekly, monthly or other cycles may be used to inform dosage for treatment of a patient with a cardiovascular, respiratory, physiological or other disorder.
Description
METHOD AND APPARATUS FOR DESIGNING A COURSE OF TREATMENT
FIELD
The present invention relates to methods and apparatus for designing a course of treatment for a medical condition, such as by determining a dosage regime of a medicament, and more particularly for the treatment of medical conditions associated with deviations in physiological parameters from normal values, as well as to related subject matter.
BACKGROUND
Physiological parameters such as blood pressure and respiratory rate are known to be important indicators of patient condition, with altered (e.g. elevated) values often associated with an increased risk of adverse events. The variability of physiological parameters over IS time can itself be associated with an increased risk of adverse events. It is important to be able to reliably measure and determine the variability in such parameters over time.
By way of illustration, mean blood pressure is well known to be a leading risk factor for cardiovascular disease (see Lim et at, Lancet, vol. 380, no. 9859, pp. 2224-2260, 2012).
However, blood pressure is also characterised by fluctuations occurring over different time-scales. Rather than representing random phenomena, those changes are the result of interactions between environmental, behavioural factors and the cardiovascular regulation system (see Parati et at, Nat. Rev. Cardiol., vol. 10, no. 3, pp. 143-155, 2013). These changes give rise to long-term (clinic or visit-to-visit) variability, mid-term (day-to-day) variability, usually assessed by home monitoring, or short-term variability, usually assessed by ambulatory blood pressure monitoring (ABPM). A recent systematic review and meta-analysis has shown that long-term blood pressure variability (BPV) is associated with cardiovascular and mortality outcomes, over and above the effect of mean blood pressure (see Taylor et at, PLoS One, vol. 10, no. 5, 2015). Limited data for mid-term and short-term BPV showed similar associations. -2 -
Variability in blood pressure and other physiological parameters over time has been studied extensively and the electronic collection and storage of data has enabled large data sets to be assembled for many different cohorts. Although valuable insights are expected to emerge by studying such large data sets, the nature of the data sets cause difficulties in such study. For example, computations based on data contained in a hospital database may be skewed because, in a hospital database, individuals with a prolonged length of stay tend to contribute many more measurements than other patients, not only because of their greater length of stay but also because they tend to be sicker and hence have higher frequency of observations.
SUMMARY
Aspects and examples of the present invention are set out in the claims and aim to address technical problems such as those described herein, and related technical problems.
I5 For example, embodiments of the disclosure may have the advantage of enabling dosage regimens to be designed based on physiological monitoring data obtained in real clinical settings. The frequency and timing of such physiological measurement may vary greatly with time and from patient to patient. Embodiments may also be able to deal with problems associated with the presence of gaps in the sequence of measurements, interspersed with periods of varying frequency of measurement. Embodiments may also be able to deal with problems associated with the fact that data for a patient who moves through a hospital from intensive care to high-dependency to normal ward to rehabilitation has now been found to show a decreasing frequency of measurement of physiological parameters, and possibly significant day/night differences in frequency of measurement.
An aspect of the disclosure provides a computer implemented method of designing a dosage regimen for the treatment of a medical condition, the method comprising: obtaining a plurality of samples of physiological parameter data, each sample being associated with a corresponding subject of a cohort of subjects and having being collected at a particular time; selecting a cyclic time period and, for each of a plurality of time intervals spanning said cyclic time period, determining a representative value of the physiological parameter for -3 -each subject based on the samples collected within said time interval, thereby to provide a time series of the physiological parameter for each subject over at least a part of a cycle of the cyclic time period; selecting, from amongst the cohort of subjects, a sub-cohort of subjects associated with at least one identifying factor; combining the time series of each of the subjects of the sub-cohort to provide a sub-cohort time series of the physiological parameter; identifying, based on the sub-cohort time series, at least one time interval of the sub-cohort time series comprising a treatable deviation of the physiological parameter, wherein the treatable deviation is associated with a medical disorder; identifying a medicament indicated for treatment of said disorder; and providing, based on the at least one identified time interval, data identifying a timing for dosage of the identified medicament for treatment of subjects associated with the at least one identifying factor.
It will be appreciated in context of the present disclosure that the time series may be represented by any array of data values or similar data structure, such as a vector, and the elements of that data structure need not be arranged sequentially (i.e. they need not be stored in a temporal sequence). All that is needed to represent a time series is that the representative value for each time interval be identifiable as belonging to that interval.
The samples of physiological parameter data for each subject may be irregularly sampled, whereby they comprise a different number of samples of physiological parameter data in each of said time intervals.
Combining the time series to provide a sub-cohort may increase the regularity of the sampling, for example the sub-cohort time series may have fewer unpopulated time intervals than the individual time series of the subjects.
The method may comprise determining the at least one identifying factor based on a time series of the physiological parameter data. The at least one identifying factor may comprise demographic data identifying a selected demographic range, such as an age range and gender. -4 -
Other identifying factors, e.g. based on other combinations of demographic and other identifiers (such as medications and/or diagnoses) may also be used. The methods described herein may comprise selecting a value of the at least one identifying factor, determining a cyclic amplitude of the sub-cohort time series, updating the value of the at least one identifying factor thereby to identify a second sub-cohort and a second sub-cohort time series having a greater cyclic amplitude, and identifying said at least one time interval comprising the treatable deviation based on the second sub-cohort time series.
The methods may comprise administering, according to the data identifying the timing, a series of doses of the medicament to a patient, associated with the at least one identifying factor.
IS The method may comprise collecting the samples of physiological parameter data from patients, and optionally subsequently treating those same patients, or other patients by administering a medicament according to the dosage regimen, e.g. administering, according to the data identifying the timing, a series of doses of the medicament.
The samples of data may be obtained from a database of values P of the physiological parameter obtained from a population of N subjects over a time period T formed of 11 time intervals /, wherein the frequency of values recorded varies between subjects such that some subjects contribute more values for one or more of the time intervals than other subjects; the method comprising b) computing, for each subject of the population, a vector Ptk according to equation (I): k u5k pk.../pkni (I) wherein Pkl, Pk 2, ...Pkri are the average values of the physiological parameter for the kth subject in the time intervals 1, 2, .. n respectively; and -5 -c) computing, for the total population of subjects, a vector Pt according to equation (II): Ni N2 Nn 1 I 1 1 Pt = pk p _Ipkni ivi 1, ro, 2 Nn NZ 2 k k=1 k =1 k=1 wherein /VI, N7, . . N"are the number of non-zero values of /5k1, px2 Pk respectively for k = 1, 2, ... N. The method may further comprise associating components of the vector Pt with their corresponding time intervals, thereby to provide said time series of the physiological parameter for each subject over at least a part of a cycle of the cyclic time period.
The method may further comprise the steps of: d) computing an average value 15T of the physiological parameter for the population over the cyclic time period according to equation (110: N1 N2 Nn (III); and _ 1 1 1 1 PT = n -N-1 Pk 1 ± N-2 Ar x2,... ± pkni n k=1 k =1 k=1 e) computing a vector,APt representing the time series of the physiological parameter by time interval according to equation (IV): 1 P -PT] (IV) Pt= [-N1 k=1 wherein the sub-cohort time series comprises the vector APE.
The time interval may be 1 hour and the cyclic time period may be a period of 24 hours. -6 -
The time interval may be 1 day and the cyclic time period may be a period of 1 week.
The time interval may be 1 month and the time period is a period of 1 year.
The total number of subjects may be at least 1,000, e.g. at least 10,000, e.g. at least 25,000, e.g. at least 50,000.
The subjects may be patients for example wherein the subjects are, or include, hospitalised patients.
The method may further comprise a step of identifying a disorder to be treated based on the output of the method.
The disorder may be a cardiovascular disorder or a respiratory disorder.
The physiological parameter may be a parameter associated with a periodic physiological process.
The physiological parameter may comprise one or more of the following: blood pressure, peripheral oxygen saturation, respiration rate, pulse rate, and body temperature.
Embodiments of the disclosure provide computer program products configured to program a processor to perform any one or more of the methods described or claimed herein. These products may be embodied in tangible non-transitory data storage media.
Embodiments of the disclosure provide an apparatus comprising a processor and a database of time series of physiological parameter data, wherein the processor is configured to perform any one or more of the methods described or claimed herein.
The time interval may be a day, in which case the cyclic time period may be a week, a month, a menstrual cycle, a gestational period, or any other cyclic time period comprising a plurality of days. Likewise, the time interval may be a week, in which case the cyclic time period may -7 -be a month, a year, a menstrual cycle, a gestational period, or any other cyclic time period comprising a plurality of weeks.
A computer implemented method of designing a dosage regimen for the treatment of a medical condition is also described. The method may account for irregularities in the sampling of data associated with normal patient care by aggregating data from large numbers of patients, perhaps from a large number of medical facilities such as hospitals. This aggregated data can then be used to identify cyclic variations in physiological parameters which variations may be associated with an adverse medical condition or event. The timing of these variations in the population (or particular demographic sub-cohorts of that population) can then be used to determine the timing and/or dosage level for the administration of medicaments associated with reducing the deviation in the physiological parameter concerned.
Advantageously, the present invention can allow variability of the physiological parameter to be computed in a manner which is resilient to data sets in which measurement gaps and variations in measurement timings occur. Further it may ensure that patients having a higher frequency of values recorded in the database do not have a greater weight in the computation than patients having a lower frequency of values. For instance, in embodiments in which the database is a hospital database, data obtained from patients with a long hospital stay do not have a greater weight in the computation of values for the population than the data from patients with shorter lengths of stay. It may also allow patterns in the variability of the physiological parameter for different sub-cohorts of patients to be identified. These lead to more appropriate treatment regimens for such sub-cohorts.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will be more fully understood from the following description of various illustrative embodiments, when read together with the accompanying drawings. It should be understood that the drawings described below are for illustration purposes only and are not intended to limit the scope of the present invention in any way. -8 -
Figure I A shows an apparatus for determining a dosage regimen for the treatment of a medical condition.
Figure 1B and Figure 1C show sets of samples of data obtained from monitoring subjects in a system such as that described with reference to Figure 1.
Figure 2 shows the variation of systolic and diastolic mean blood pressure with age for men and women with the indicated standard error bars.
Figure 3 shows how blood pressure varies seasonally according to the month of the year.
Figure 4 shows how blood pressure varies according to the day of the week.
Figure 5 shows the 24-hour systolic and diastolic blood pressure variability for patients for seven age groups (values ascend with age group).
Figure 6 shows the 24-hour systolic and diastolic blood pressure variability for patients in three major age groups (values ascend with age group).
DESCRIPTION OF VARIOUS EMBODIMENTS
Embodiments of the present disclosure exploit the ability of computer hardware to collect and collate physiological parameter data (e.g. blood pressure values) from large cohorts of patients to overcome problems associated with the irregular sampling of that data. The disclosure enables patient data from large cohorts of patients to be mined to identify sub-cohorts of patients which exhibit a particular temporal (e.g. cyclic) variation in a physiological parameter. Such a cyclic variation may be impossible reliably to identify in the data collected from a single patient, and may be masked in the data from the cohort as a whole because the relevant effect may be obscured in the cohort as a whole -e.g. by the high degree of random variation and non-cyclic effects. This can enable a sub-cohort exhibiting such a cyclic variation, and the timing of that cyclic variation, to be identified thereby to design an appropriate medicament and dosage regimen for that sub-cohort. Such dosage -9 -regimens may specify the particular medicament, and the dose of that medicament which is to be provided at a series of time intervals within a particular cyclic time period -e.g. at a particular hour of the day, day of the week, season or month of the year, or any other such interval within any other such cyclic time period.
Uncovering a hidden sub-cohort and a hidden cyclic variation can enable an appropriate medicament to be provided in that sub-cohort to reduce deviations in the relevant physiological parameter(s) from medically acceptable norms thereby reducing the incidence of adverse events, such as deterioration in a patient's health.
For example, by identifying a particular group of patients exhibiting a particular cyclic daily variation in blood pressure, a course of treatment can be designed for that patient group which acts to reduce blood pressure during the time at which blood pressure is likely to be highest thereby to reduce the prevalence of adverse events caused by hypertension in that particular patient group.
Figure lA shows a system 1 comprising a plurality of medical facilities 200, 200', 200", and an apparatus 100 for determining a dosage regimen for the treatment of a medical condition.
The apparatus 100 comprises a database of patient data 10, a processor 14, and a database of medicament data 12. The apparatus 100 may also comprise a treatment provider 16. The processor 14 is coupled to the database of patient data, and to the database of medicament data 12, and may also be coupled to control the treatment provider 16. The treatment provider 16 may be connected for communication with one or more of the medical facilities 200, 200' 25, 200" for providing treatment control data (e.g. a dosage regimen) for use in treatment of patients at the medical facility 200.
Each of the medical facilities 200, 200', 200" comprise a plurality of patient monitoring facilities 202 each adapted to provide a plurality of time series of physiological parameters 204 obtained by monitoring of the patients. The patient monitoring facilities 202 may comprise data collection hardware disposed at a patient's bedside, or carried by medical personnel, and configured to communicate patient data to the apparatus 100 over a communications network such as a wide area communications network. Due to the constraints necessarily imposed by patient care the patient monitoring facilities 202 may perform only intermittent, ad hoc, data collection. The time series of physiological parameters obtained from each patient may thus be irregularly sampled, and may be of short duration (time from first to final measurement).
Each of the facilities 200, 200', 200" provide this physiological parameter data, and demographic data associated with each patient, to the apparatus to be recorded in the database of patient data 10. Examples of physiological parameters include blood pressure (systolic and diastolic), heart rate, peripheral oxygen saturation, respiration rate, blood sugar levels, and body temperature.
The database of patient data 10 thus comprises a plurality of time series of physiological parameter data, each time series comprising measurements of a particular physiological parameter of a particular corresponding patient. As noted above, the physiological parameter data may be sampled irregularly. That is to say, for example, more samples may have been taken in some time intervals than in others e.g. more on a particular day of the week, month of the year, or during a particular hour of the day than in other similar intervals.
Each time series of physiological parameter data is associated with a corresponding patient, and the database of patient data 10 also comprises demographic data for each of those patients. This data may indicate, for example, the age, gender, ethnic group, or weight of the patient. Any one or more of these demographic indicators may be associated with each patient by the demographic data.
The database of patient data 10 may comprise vital-sign observations recorded by nursing staff in acute hospitals over an extended period of time for example up to 3 years. The physiological parameter stored in the database may comprise systolic blood pressure (SBP) and diastolic blood pressure (DBP) in adult in-hospital patients. One example of the database comprises data from 59,712 admissions. Typically the database comprises at least two blood pressure (BP) measurements for each patient separated by more than 24 hours. For example, that database comprised a total of 2,219,042 measurements with a median number of 23 measurements per patient. This is just one example of the temporal sampling of the time series of physiological parameter data. A greater or lesser, and more or less even sampling of the data may be used. When the data is viewed over a particular cyclic time period -such as a day, week, or year, there may be time intervals (such as overnight, or even during the lunch break of the nursing staff in a particular medical facility) during which the physiological parameter data is more frequently or more sparsely sampled than for other periods. Figure 1B and Figure IC each show a plot of one time series of physiological parameter data. The x-axis of these plots is the hour of the day at which the samples of physiological parameter were collected, and the y-axis of these plots is the systolic blood pressure in mmHg. The time series illustrated in Figure 1B comprises 23 samples of blood pressure data collected over 4.6 days, whereas the time series illustrated in Figure IC comprises 43 samples collected over 12.8 days. The scatter of data points in these plots indicates the individual samples of data, whereas the solid lines indicate the average in each time interval (in this case, hour) of the cyclic time period (in this case, day). It can be seen from these two plots that very often data is not evenly sampled throughout a 24 hour daily cycle -some hours may comprise multiple measurements, some may comprise fewer or none at all. This makes it extremely challenging to determine whether, or not, any systematically treatable variation may be present in the data. In the context of the provision of clinical care (the context in which the vast majority of such data is sampled) it may not be possible or desirable to sample the data more regularly, nor over a longer total time period (e.g the duration of the hospital stay). It is therefore a significant technical problem to extract meaningful information from this data to inform patient care -e.g. to enable new, and more effective, dosage regimens to be designed and/or administered.
In addition to the database of patient data 10, the apparatus 100 comprises a database of medicament data 12. The database of medicament data 12 comprises identifiers of a plurality of different medicaments, each indicated for the treatment of a particular disorder (such as hypertension) e.g. a deviation in a physiological parameter from a medically acceptable or non-pathological range of values. For example, medicaments may be indicated for treatment of the reduction, or increase of blood pressure. The database may comprise data indicating a delay time between administering the medicament and it becoming effective to modulate (to increase or decrease) the relevant physiological parameter of the patient.
The processor 14 may comprise any appropriately programmed general purpose data processor. The processor 14 may be configured to pre-process the time series of physiological parameter data to normalise the weighting given to each individual patient as explained elsewhere herein.
After this optional pre-processing, the processor 14 is configured to obtain a time series of the physiological parameter data from the database 10 and to determine a representative value of that physiological parameter for each of a plurality of time intervals of a cyclic time period -such as one representative value for each month of the year, each day of the week, or each hour of the day. For example, to determine the time series of a physiological parameter through the months of the year, the processor 14 is configured to operate as follows.
For each patient time series, a 12-dimensional vector of the physiological parameter values is computed according to equation (1): Pk (1) month Pk F Jan, PkFeb,Felv PDeci where pk,an, Pk Feb, ..* are the averages of all physiological parameter values recorded in January, February and so on for the kih patient. For any patient, certain time intervals in this time series of physiological parameter data may not be assigned any value. For example, if the kat patient was hospitalised in January and February, then the first two entries of the vector P,I,c,e"b will comprise data values, whereas the remaining ten components of Pikbentb may be absent -for example, the processor 14 may assign these items of patient data to a non-numeric indicator such as be indicated as not a number (e.g. NaN). Next, the processor 14 computes a vector of average monthly values according to equation (2): Pmonth = [Nia k=1 k=1 (2) Njan NDec Pk Pk Dec] where Man is the number of nonzero values Pk jan for k = 1, , N; P _ kFeb is the number of non-zero values P _ kFeb and so on. The parameter vector according to the month of the year LIP,,,,"th is then computed by subtracting from each component of Praoath the yearly mean year that 1S:
I
Njan NDec iPmonth =NJan Pklan ryear, *** NDec PkDec Pyear] k=1 where P year is the average of the components of Prnk oath and it is computed as: Klan NDec 1 1 _k 1 P year = P Jan ± ***/ ***/ r 15kDeci 12 Arjan lvDee k=1 k=1 As another example, the processor 14 may compute the time series of a physiological parameter for an individual patient according to day of the week by operating as follows. For each patient, a 7-dimensional vector with components corresponding to the parameter values for each day of the week is computed according to equation (5): Pgay = [Pk Mon,F9kTue, ***/ Pk Sun (5) where, PkmomPkTue, Pksun is the average of the values of the relevant physiological parameter for the kth patient recorded on Monday, Tuesday and so on. As noted above, if the parameter has not been sampled on any particular day the relevant value may comprise a non-numeric indicator. The vector of average daily values of that parameter, for all patients, is then computed according to equation (6): NMon NSun 1 1 I rk P day = [ PkSun ***/ "Sun] Nmo k=1 mSun I k=1 (3) (4) (6) -14 -As before, the different summation indices A/mon, Nsua reflect the fact that not all N patients may have had vital-sign observations for each day of the week.
The parameter vector according to the day of the week APday is computed by subtracting from each component of the vector Pday the overall weekly average P week, which is simply the average of the seven components of Pday.
As another example, the processor 14 may compute variability of a physiological parameter for an individual patient according to hour of the day by operating as follows. Firstly a 24-dimensional vector is computed according to equation (7): hour= [pk 0, pk pk 23 (7) h where Pkj is the average of all values of the physiological parameter for the kth patient recorded between the hour j and j+/ for j-O,...,23. An individual patient therefore only contributes one vector PLur of average values of parameter values regardless of the length of stay and number of BP measurements.
The 24-hour parameter vector, for any group of patients (e.g. a sub-cohort selected based on demographic data) is then computed according to equation (8): N23 hour = L 1 PkO, *** Pk231 No N23k=1 k=1 The different components of Phou,-are the average values of the relevant physiological parameter, across all patients in that group, in each of the corresponding 1-hour time intervals. The summations N0, ..., N23 reflect the fact that not all patients have measurements recorded at each hour of the day and some components ofit,' Pnour are empty for most patients in the database. (8)
The daily time series of the physiological parameter according to the hour of the day can be provided by Phou,. Optionally, the daily time series of the physiological parameter according to the hour of the day can in some instances also be provided by AP hour which can computed by subtracting from each component of the vector P_hour the overall daily average of the parameter vector.
In any of these examples, having determined the time series for each individual patient, the processor 14 may then determine an average time series for the cohort of patients and/or for a sub-cohort selected from amongst that cohort. Such a sub-cohort may be selected based on analysis of the physiological parameter data itself, or by selecting a sub-cohort associated with one or more ranges of demographic data, such as particular age groups.
The examples outlined above have explained how the processor 14 can determine the time series of a physiological parameter values in each of the intervals which span particular cyclic time periods. Other time intervals of other cycles may also be used -for example the day/week/month of a period of gestation, the day/week of the menstrual cycle. The hour/minute of a sleep cycle, or any other repeating/cyclic phenomena which enables irregularly sampled data collected from multiple patients to be treated together.
The treatment provider comprises a data output resource for providing data and/or control signal output. Such an output resource may comprise a printer for printing human readable instructions to be included in a prescription, or for labelling the packaging of a medicament, for example such as identifying items on a blister pack of tablets, or for example for controlling operation of an automatic dosing machine, such as in a manufacturing facility for manufacturing doses of the medicament, or for controlling a dosing machine at a patient's bedside.
In operation, the processor 14 obtains a plurality of time series of physiological parameter data from the database. It then identifies a series of periodic time intervals, which together span a cyclic time period -for example, hours of the day, days of the week, or months of the year. The processor 14 then determines the time series of physiological parameter data for each patient by allocating each sample to one of these time intervals according to the time at which each sample was collected (e.g. as indicated in the database of patient data). This provides a set of time series of physiological parameter data for the entire cohort of patients, one time series per patient. Any cyclic variation in these time series of data is typically masked by other factors which provide variability across the cohort as a whole. To uncover the presence of a cyclic variation within a particular sub-cohort, the processor must identify the relevant sub-cohort.
Different methods may be used to do this.
A first method is to select sub-cohorts based on the demographic data, such as an age range and/or gender, and/or some other identifying factor.
A second method is to identify sub-cohorts based on the time series themselves, for example based on a data mining method. This may be done by identifying a group of patients associated with at least one identifying factor, determining a cyclic amplitude of the sub-cohort time series (e.g. the presence and size of a dip or peak in the time series for that subcohort). The value of the at least one identifying factor can then be reselected thereby to identify a second sub-cohort, and the cyclic amplitude determined again. This can enable a sub-cohort to be identified based on the data itself. Other data mining methods, such as clustering, are contemplated.
Operation according to the first of these two methods will now be described, but both methods are intended to be encompassed within the present disclosure when read as a whole. 25 The time series of physiological parameter data from patients belonging to a particular sub-cohort (e.g. a particular range of demographic data) are selected from the database. For example, a sub-cohort may comprise a particular age range. The processor 14 may then determine the average of the physiological parameter for each patient across the entire cyclic time period (e.g. if the cyclic time period as a year, the yearly mean as explained above). The processor then determines a time series for each patient by providing a single representative data value for each time interval. This representative value may comprise a measure of central tendency such as the mean (as described in the examples given above). If the cyclic average has been determined for each patient, this may be subtracted from the representative values for each time interval as described above with reference to the monthly/daily variations across the period of a year/week.
A time series of physiological parameter data can then be determined for the sub-cohort as a whole. This may be done by combining the time series of representative values for each of the patients in the sub-cohort into a single time series -e.g. based on the central tendency (e.g. mean, mode, or median) of the representative values from all patients in each of the time intervals which make up the relevant cyclic period.
The processor 14 is configured to identify the presence of any significant cyclic variation in this sub-cohort time series of physiological parameters for the sub-cohort. In the event that a significant cyclic deviation from physiologically/medically acceptable values is identified, IS the processor 14 first identifies, from the medicament database, a medicament for treating such a deviation (e.g. by reducing its magnitude or duration). The processor may then determine a time, or series of times, during the cyclic time period, at which the medicament is to be administered to counteract or reduce the identified deviation.
In the event that no such deviation is identified, the processor may change the range of demographic data used to select the sub-cohort, and then reassemble a new sub-cohort time series associated with this new demographic data range. The process may then repeat the above-described steps to determine whether a significant cyclic variation of the physiological parameter occurs in this new demographic group (whether expanded, or refined) and in the event that such a variation is indicated for this new demographic group it may determine a course of treatment with a particular medicament as described above.
The course of treatment can then be administered to patients which match the range of demographic data used to generate the dosage regimen Patient and Condition -18 -The terms treatment" or "treating", as used herein, encompass therapeutically regulating, preventing, improving, alleviating the symptoms of, and/or reducing the effects of a medical condition.
The term "patient" as used herein refers to a human patient. The patient may be a male patient or a female patient. In an embodiment, the patient is at least 40 years old, e.g. at least 50 years old, e.g. at least 60 years old, e.g. at least 70 years old, e.g. at least 80 years old. In an embodiment, the patient is a male patient who is at least 50 years old, e.g. at least 60 years old, e.g. at least 70 years old, e.g. at least 80 years old. In another embodiment, the patient is a female patient who is at least 40 years old, e.g. at least 50 years old, e.g. at least 60 years old, e.g. at least 70 years old, e.g. at least 80 years old.
In an embodiment, the patient is a hospitalised patient.
The term "hypertension" as used herein refers to a sustained elevation of resting systolic blood pressure of at least 120 mmHg, e.g. at least 125 mmHg, e.g. at least 130 mmHg, e.g. at least 135 mmHg, e.g. at least 140 mmHg. In some instances, the patient will also have a sustained elevation of resting diastolic blood pressure of at least 60 mmHg, e.g. at least 65 mmHg, e.g. at least 70 mmHg, e.g. at least 80 mmHg, e.g. at least 90 mmHg. In some instances, the patient to be treated will have a sustained elevation of resting systolic blood pressure of at least 125 mmHg and resting diastolic blood pressure of at least 60 mmHg, e.g. at least 65 mmHg, e.g. at least 70 mmHg. In some instances, the patient will have a sustained elevation of resting systolic blood pressure of at least 130 mmHg and resting diastolic blood pressure of at least 65 mmHg, e.g. at least 70 mmHg.
Hypertension may be classified as primary or secondary. Primary hypertension (also known as "essential hypertension") is hypertension with no known cause and is more common. Secondary hypertension is hypertension with an identified cause, such as primary aldosteronism, renal parenchymal disease (e.g. chronic glomerulonephritis or pyelonephritis, polycystic renal disease, connective tissue disorders, or obstructive uropathy), renovascular disease, and sleep apnoea. Other much rarer causes include pheochromocytoma, Cushing syndrome, congenital adrenal hyperplasia, hyperthyroidism, hypothyroidism (myxedema), primary hyperparathyroidism, acromegaly, coarctation of the aorta, and mineralocorticoid excess syndromes other than primary aldosteronism.
Hypertension and night-time surges in blood pressure can be diagnosed by sphygmomanometry. Preferably, ambulatory blood pressure monitoring (APBM) is used to determine the blood pressure profile of the patient over the desired time period, e.g. over a 24-hour period. Suitable APBM devices for recording blood pressure are known in the art and include auscultatory devices and oscillometric devices. Other techniques useful in the diagnosis of hypertension include urinalysis and analysis of the urinary albumin:creatinine ratio; blood tests (e.g. analysis of levels of lipids, creatinine, potassium, sodium, fasting plasma glucose, and thyroid-stimulating hormone); renal ultrasonography; evaluation for aldosteronism; electrocardiography; and evaluation for pheochromocytoma or sleep disorders.
IS Pharmaceutical Compositions, Routes of Administration and Posology The anti-hypertensive agent may be administered in the form of a pharmaceutical composition comprising the anti-hypertensive agent and a pharmaceutically acceptable carrier or excipient. Methods of preparing pharmaceutical compositions are known, or will be apparent, to those skilled in this art, for example from literature such as Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Company, 1990.
Administration of the anti-hypertensive agent can be carried out via any of the accepted modes of administration or agents for serving similar utilities. As is known in the art, therapeutic agents can be administered orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders (including lyophilized powders for reconstitution), solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
Preferably, the anti-hypertensive agent is administered orally.
-20 -The amount of therapeutic agent to be administered will vary depending upon a variety of factors including the activity of the specific agent employed, the metabolic stability and length of action of the agent, the age, body weight, general health, sex, diet, mode of administration, rate of excretion, the severity of the condition and the patient undergoing therapy. By way of illustration, a therapeutic agent can be administered to a patient at a dosage level in the range of from about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art.
The present invention is further illustrated by the following example, which is provided for illustrative purposes only. The example is not construed as limiting the scope or content of the disclosure in any way.
Introduction
Using a large database of vital-sign observations recorded by nursing staff in acute hospitals over a period of just over 3 years, the characteristics of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in adult in-hospital patients were investigated. The data from 59,712 admissions, with at least two blood pressure (BP) measurements separated by more than 24 hours, were included in the study. A total of 2,219,042 measurements with a median number of 23 measurements per patient were analysed. Blood pressure variability (BPV) over different timescales was computed in a manner which ensured that patients with prolonged lengths of stay did not have a greater influence on these profiles than patients with shorter lengths of stays.
Methods Database -21 -Data were obtained in four acute hospitals and recorded using a computer system which facilitates the recording of vital-sign values and enables the recognition of physiological deterioration on the ward.
Exclusion criteria As short-term BPV is usually assessed using 24-hour variability, this required the availability of both day-time and night-time data. Admissions that did not have at least one observation during night-time (midnight-7 am) and at least one observation during daytime (10 am-9 pm) were therefore excluded, such that there were at least two measurement sets per admission in the resulting dataset. Also excluded were admissions for which the difference between the first and last observations was less than 24 hours.
Data pre-processing In any hospital database, some individuals with a prolonged length of stay contribute many BP measurements, not only because of their greater length of stay but also because they tend to be sicker and hence have a higher frequency of vital-sign observations. The data were therefore pre-processed so that the BP data from patients with a long hospital stay did not have a greater weight in the computation of population BP and BPV (over any timescale) than the data from patients with shorter lengths of stay.
1) BPV according to the month of the year BPV according to the month of the year was computed as follows. For each patient, a 12-dimensional vector of BP values was computed according to equation (9): Pmk onth = rkJan, Pk Feb, *** 15k Dec (9) where P -k janfrPk Feb, *** are the averages of all blood pressure values recorded in January, February and so on for the kth patient. For any patient, most of the entries were not assigned any value. For example, if the kth patient was hospitalised in January and February, then the -22 -first two entries of the vector Pikm.,,,th will be numerical, whereas the remaining ten components of Pink onthwill be indicated as not a number (e.g. NaN).
Next, a vector of average monthly values was computed according to equation (10): Pmonth = Arran IVJan Mime (10) lc 1 p P-k Deci Ian A/Dec k=1 k=1 where Njah is the number of nonzero values pkian for k = 1, ...,N; PkFeb is the number of non-zero values PkFeb and so on.
The BPV vector according to the month of the year 4BP -month was computed by subtracting from each component of month the yearly mean P year that is: NJan Nnec
I
AR Pnrionth = [ ' Jan *-* m1 ' Dec ' IF yearJ (11) -" N1 Jan k=1 Deck=1 where P year is the average of the components of itont h and it s computed as: N Jan NDec 1 1 1 P year = PkJan + *** + *** + PkDec] 12 N JanNDec k1 k=1 2) BPV according to day of the week: For each patient, a 7-dimensional vector with components corresponding to the BP values for each day of the week was computed according to equation (13): pk -[Uric Pk Uric (13) day I Mom ' Tuei *** ' Sun where, P -kMoni PkTue,***1 Pk Sun is the average of all blood pressure values for the kth patient recorded on Monday, Tuesday and so on. (12)
-23 -The vector of average daily BP values, for all patients, was computed according to equation (14): 1 07k Pk Sun] (14) Pday = [NM Sun, * ** As before, the different summation indices Nmon, ...,Nsur, reflect the fact that not all N patients had vital-sign observations for each day of the week.
The BPV vector according to the day of the week AB Pday was computed by subtracting from each component of the vector Pday the overall weekly average P Week. which is simply the average of the seven components of Pday.
3) 24-hour BPV To compute the BPV according to the hour of the day, a 24-dimensional vector was first computed according to equation (15): h pkour [pk pk Pk 23 (15) where Pki is the average of all blood pressure values for the kih patient recorded between the hour j and "fr./ for j-0,...,23. An individual patient therefore only contributes one vector Pircour of average values of blood pressure regardless of the length of stay and number of BP measurements.
The 24-hour BPV vector, for any group of patients, was computed according to equation (16): -24 -No Nz3 (16) PhOLII" = PICO *** 1 I pk23] No k=1 N23 k=1 The different components of Phour are the average blood pressure values, across all patients in that group, of the corresponding 1-hour bins. The summations No, ..., N23 reflect the fact that not all patients have measurements recorded at each hour of the day and some components of Pnour are empty for most patients in the database.
Demographics Table 2 below shows the total number of admissions, together with the percentage of admissions for each of eight age groups, the median length of stay (LOS) and the type of admission (medical, surgical or other). A total of 59,712 patients who had at least two measurements (including at least one at night), with the time between the first and the last measurement greater than 24 hours, were included in the study. The study contained 2,219,042 BP measurements with a median number of 23 measurements per patient. The median length of stay (defined as the time difference between the first and the last BP measurements) was 4.2 days.
Num of Admis. % of All Age [years] LOS [days] Medical Surgical Other [1l)) ] [ ] [ ] All 59712 100.0 64.2 4.2 49.4 47.9 2.7 Men 29652 49.7 64.1 4.3 47.8 49.4 2.7 Women 30060 50.3 64.3 4.2 51.0 46.4 2.6 18-29 4182 7.0 23.7 2.9 41.9 57.1 1.0 30-39 3824 6.4 34.5 3.0 41.0 57.5 1.4 40-49 5245 8.8 45.1 3.5 40.7 57.2 2.1 50-59 8098 13.6 54.7 3.8 41.8 55.0 3.2 60-69 10481 17.6 64.9 4.1 44.2 51.7 4.1 70-79 12675 21.2 74.5 4.7 50.6 46.3 3.1 80-89 11125 18.6 84.2 5.9 61.1 36.5 2.3 90+ 3825 6.4 92.9 6.6 72.2 26.7 1.1
Table 2
-25 -The four decades from 50 to 89 account for nearly three-quarters of all admissions (71%). Men and women are equally represented in the database (approximately 30,000 admissions each) with a median age of 64.2 years. Nearly half of all admissions were medical (49.4%) and half were surgical (47.9%). As expected there were many more medical admissions for elderly patients (e.g. 72.2% for the 90+ year age group) than younger patients (41% for the 30-39 year age group). Around half of all admissions (51.3%) were assigned the diagnosis code ICD-10 (data not shown). In terms of the ethnicity of the patients, the main ethnic group was white (78.6% of total), with the remaining patients falling into a range of other ethnic groups (data not shown).
Since the database was acquired from 59,712 admissions and contains 2,219,042 BP measurements, the relationships of BP and its variability over different timescales and/or with age estimated in the analyses are considered to reflect true physiological variation.
I5 Results Variation with sex and age Table 3 shows the mean systolic BP (SBP) and diastolic BP (DBP) for men and women, for the eight age groups from 18-29 to 90+ years.
All Mean SBP Mean DBP Men Women All Men Women All 127.2 127.6 126.7 69 70.4 67.6 18-29 117.2 121.6 113.4 65.9 66.7 65.2 30-39 119 124.1 114.9 69.4 72.2 67.1 40-49 122.3 125.6 119.3 71.2 74.2 68.5 50-59 125.3 127.1 123.3 71.4 73.8 68.8 60-69 127.5 127.7 127.1 69.7 71.5 67.5 70-79 130.0 129.0 131.2 68.0 69.1 66.8 80-89 132.0 130.0 133.8 68.0 68.2 67.9 90+ 133.3 130.1 135.0 68.5 67.8 68.9
Table 3
-26 -Figure 2 shows the variation of systolic and diastolic mean blood pressure with age for men and women with the indicated standard error bars.
BPV according to month of the year Table 4 shows the number of admissions per month in the database and the average systolic and diastolic BP for each month.
Month Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Freq SBP 2245 2975 3269 3421 3557 3858 4090 4383 4415 4426 4387 4345 Mean SBP 128.1 127.2 127.7 127.8 128.4 127.7 127.3 127.1 126.8 127.2 127.6 127.9 Freq DBP 2245 2974 3269 3421 3557 3858 4090 4382 4415 4426 4387 4345 Mean DBP 69.3 69 69.2 69.1 69.3 69 68.9 69.1 69.1 69 69.4 69.1
Table 4
Figure 3 is a graphical plot of Equation (3) for AP,,,0"ti" and shows how BP varies seasonally according to the month of the year.
BPI according to day of the week Table 5 shows the number of patients in the database with BP measurements on any given day of the week, and the average systolic and diastolic BP for each day.
Day Mon Tue Wed Thu Fri Sat Sun Freq SBP 40384 43034 43890 44889 45186 44770 41724 Mean SBP 128.7 127.8 127.5 127.4 127.4 127.6 128.2 Freq DBP 40382 43029 43882 44886 45186 44761 41722 Mean DBP 69.9 69.3 69.1 69.1 69.1 69.3 69.7
Table 5
Figure 4 is a graphical plot of the APda, data and shows how BP varies according to the day of the week.
-27 - 24-hour BPV -circadian variations Table 6 shows the number of BP measurements and the average values of systolic and diastolic BP, across the entire cohort, calculated for each one-hour bin. The table shows that the fewest measurements are made between 3 and 4 am (16,273), with the greatest number of measurements being made in the early morning between 5 and 6 am (45,759) and again soon after the night shift starts, between 8 and 9 pm (44,265). The mean SBP and DBP values in the lowest two rows of the table are the components of the vector Phour from equation (8) evaluated for the systolic and diastolic BP.
I lour 0 1 2 3 4 5 6 8 9 10 11 Frequency 20766 19864 18055 16273 26415 45759 42739 28023 28082 37185 42217 36244 Mean SBP 125.7 125.1 125.3 125.8 128.4 129.2 129.3 129.8 126.9 125 124.6 125.6 Mean DBP 67.2 66.9 66.9 67.2 69.0 69.7 69.8 69.7 68.7 68.4 68.5 68.7 hour 12 13 14 15 16 17 18 19 20 21 22 23 Frequency 31603 33231 37480 41704 41013 37048 34203 39151 44265 39301 30631 24168 Mean SBP 124.8 124.3 125.1 126.1 127.5 128 127.7 127.6 128 128.1 127.5 126.5 Mean DBP 67.7 67.3 68.1 68.7 69.2 69.1 68.8 68.9 69.1 69.0 68.6 67.7
Table 6
To obtain population plots of 24-hour BPV, the individual plots were averaged across all patients in the database (each patient contributing one set of measurements), with the results for SBP and DBP displayed in 10-year age groups in Figure 5 and in three major age groups in Figure 6.
Discussion Variation with sex and age As shown in Figure 2, there was an approximately linear trend of increasing mean systolic BP with age, and a quadratic trend of first increasing, and then decreasing mean diastolic BP for both men and women. The variation of systolic BP with age is much greater in women than men.
-28 -BPI/ according to month of the year Figure 3 shows how BP varies seasonally according to the month of the year. It can be seen that lower values of blood pressure are recorded during the summer season (July to October) and higher values are recorded during the winter (December to April). This pattern is largely consistent with results previously reported in the literature (see, e.g., Kim et at, Am. J. Hypertens, pp. 1-8, Dec. 2017).
BP V according to day of the week Figure 4 shows how BP varies according to the day of the week. A low BP was lowest at the weekend and highest on Monday. Once again, this pattern is largely consistent with results previously reported in the literature (see, e.g., Kim et al. "yttiora). The elevation of BP on Sunday may be explained by the fact that Sunday is the most popular day for hospital visits in the United Kingdom, where the patients were based.
24-hour BPI/ -circadian variations' Figure 5 shows the average 24-hour BP profiles for men and women for seven age groups, while Figure 6 shows the same data aggregated into 3 major age groups. There are three main observations which can be made from these data.
Firstly, the ambulatory blood pressure monitoring (ABPM) literature reports a typical 24-hour systolic blood pressure profile in which systolic blood pressure decreases at night during sleep and increases during the day (see Clark et at, J. Chronic Dis., vol. 40, no. 7, pp. 67181, 1987; Giles, J. Hypertens. Suppl., vol. 23, no. 1, pp. S35 S39, 2005; and Biaggioni, Hypertension, vol. 52, no. 5, pp. 797-798, Nov. 2008). A typical 24-hour profile is characterised by a marked decline in systolic blood pressure during sleep (usually around 10- 3 0 20% lower than the mean daytime value), followed by a surge in the early morning coincident with arousal from overnight sleep. However, this profile can only be seen in the younger age groups (up to 40-49 for men and 30-39 for women). For all other age groups, -29 -there is a nocturnal surge in the systolic BPV profile, the amplitude of which increases with age. The night-time profile switches gradually from a trough at the end of the night (dipping pattern) to a peak which becomes more pronounced with age.
Secondly, the systolic BP profiles for women are much more spread out than those for men.
Women in the 18-29 age group have a mean systolic BP of 113.7 mmHg (averaged across the 24-hour profile), with a nocturnal dip in the profile at 110.9 mmHg. Men in the same age group have a mean systolic BP of 121.5 mmHg (7.9 mmHg higher than women), with a nocturnal dip at 118.4 mmHg For the oldest age group (90+ years), women have a mean systolic BP of 134.4 mmHg, with a nocturnal rise in the profile at 139.8 mmHg. Men in the same age group have a mean systolic BP of 129.0 mmHg (5.4 mmHg lower than women), with a nocturnal rise at 135.7 mmHg. The second observation is brought into sharper focus by aggregating the data into 3 major age groups: young (18-39), middle-age (40-59) and elderly (60+) (see Figure 6). Young women have a 24-hour systolic BPV profile with a nocturnal dip, like young men, but with much lower BP values. In middle age, there is little or no dipping at night for both sexes, but again the profile for women consists of lower systolic BP values, although the difference between sexes is reduced. For elderly patients, the situation has reversed: the profile for women is on a higher baseline than that of men, with a more pronounced nocturnal rise.
Thirdly, the diastolic BPV patterns are less clear, although there is also a nocturnal surge in diastolic BP for both elderly men and women. In contrast to the systolic BPV profiles, the diastolic BPV profiles are less spread out for women than for men. The highest diastolic BPV profile for men is for the 40-49 age group, after which the values of diastolic BP (as already shown in Figure 5) decrease with age.
Previous studies of hypertension occurring at night-time generally focus on only two categorical variables: nocturnal hypertension and non-dipping. However, since these variables are expressed as mean values, they do not capture the phenomenon of night-time surge in blood pressure. Through use of the present methods, a hitherto unobserved surge in nocturnal blood pressure has been revealed.
As noted above, the processor of the apparatus 100 may be configured to perform optional data pre-processing to ensure that patients who stay in hospital for very long periods of time or very frequently do not skew the data. For example, this may be done by determining a weighting for each patient time series based on the duration of the time series and/or the number of samples it contains. For example, the data from each time series may be resampled so that each time series contributes a selected number of samples in each of a plurality of time intervals spanning a cyclic time period -e.g. one representative value per time interval. Resampling may be achieved by using a measure of central tendency in each interval (such as the mean, mode, or median) to provide a single representative value in that time interval. In time intervals in which no data has been sampled, a substitute value may be used -such as one obtained by interpolation the median value may also be used as a substitute. Other methods may also be used to ensure that data from patients with a long hospital stay do not have a greater weight in the computation of population physiological parameter data (over any timescale) than the data from patients with shorter lengths of stay. It will be appreciated IS in the context of the present disclosure that such data pre-processing may be done to the patient data in the patient database prior to operation of the methods described herein.
The data processing and other functionality described and claimed herein may be provided by a general purpose processor, which may be configured to perform a method according to any one of those described or claimed herein.
In some examples the controllers, processors, and other types of logic described and/or claimed herein may comprise digital logic, such as field programmable gate arrays, FPGA, application specific integrated circuits, ASIC, a digital signal processor, DSP, or by any other appropriate hardware. In some examples, one or more memory elements can store data and/or program instructions used to implement the operations described herein Embodiments of the disclosure provide tangible, non-transitory storage media comprising program instructions operable to program a processor to perform any one or more of the methods described and/or claimed herein and/or to provide data processing apparatus as described and/or claimed herein. Analogue control circuits may also provide at least a part of this control functionality.
An embodiment provides an analogue control circuit configured to perform any one or more of the signal processing methods and/or logic described herein.
-31 -Databases may be provided by suitably configured data storage devices such as volatile or non-volatile memory storage devices. Data communication between such storage devices and the processors described herein may be provided by wired or wireless communications protocols.
With reference to the drawings in general, it will be appreciated that schematic functional block diagrams are used to indicate functionality of systems and apparatus described herein. It will be appreciated however that the functionality need not be divided in this way, and should not be taken to imply any particular structure of hardware other than that described and claimed below. The function of one or more of the elements shown in the drawings may be further subdivided, and/or distributed throughout apparatus of the disclosure. In some embodiments the function of one or more elements shown in the drawings may be integrated into a single functional unit.
The above embodiments are to be understood as illustrative examples. Further embodiments are envisaged. It is to be understood that any feature described in relation to any one embodiment may be used alone, or in combination with other features described, and may also be used in combination with one or more features of any other of the embodiments, or any combination of any other of the embodiments. Furthermore, equivalents and modifications not described above may also be employed without departing from the scope of the invention, which is defined in the accompanying claims.
All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples given are illustrative only and not intended to be limiting. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs It is to be understood that while the disclosure has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (21)
- -33 -CLAIMS1. A computer implemented method of designing a dosage regimen for the treatment of a medical condition, the method comprising: obtaining a plurality of samples of physiological parameter data, each sample being associated with a corresponding subject of a cohort of subjects and having being collected at a particular time; selecting a cyclic time period and, for each of a plurality of time intervals spanning said cyclic time period, determining a representative value of the physiological parameter for each subject based on the samples collected within said time interval, thereby to provide a time series of the physiological parameter for each subject over at least a part of a cycle of the cyclic time period; selecting, from amongst the cohort of subjects, a sub-cohort of subjects associated with at least one identifying factor; combining the time series of each of the subjects of the sub-cohort to provide a sub-cohort time series of the physiological parameter; identifying, based on the sub-cohort time series, at least one time interval of the sub-cohort time series comprising a treatable deviation of the physiological parameter, wherein the treatable deviation is associated with a medical disorder; identifying a medicament indicated for treatment of said disorder; and providing, based on the at least one identified time interval, data identifying a timing for dosage of the identified medicament for treatment of subjects associated with the at least one identifying factor.
- 2. The method of claim 1, wherein the samples of physiological parameter data for each subject are irregularly sampled, whereby they comprise a different number of samples of physiological parameter data in each of said time intervals.
- 3. The method of claim 2 wherein combining the time series to provide a sub-cohort increases the regularity of the sampling.
- -34 - 4. The method of any preceding claim comprising determining the at least one identifying factor based on a time series of the physiological parameter data.
- 5. The method of any preceding claim wherein the at least one identifying factor comprises demographic data identifying a selected demographic range.
- 6. The method of any preceding claim comprising selecting a value of the at least one identifying factor, determining a cyclic amplitude of the sub-cohort time series, updating the value of the at least one identifying factor thereby to identify a second sub-cohort and a second sub-cohort time series having a greater cyclic amplitude, and identifying said at least one time interval comprising the treatable deviation based on the second sub-cohort time series.
- 7. The method of any preceding claim, further comprising administering, according to the data identifying the timing, a series of doses of the medicament to a patient, associated with the at least one identifying factor.
- 8. The method of any preceding claim, wherein the samples are obtained from a database of values P of the physiological parameter obtained from a population of AT subjects over a time period T formed of 71 time intervals t, wherein the frequency of values recorded varies between subjects such that some subjects contribute more values for one or more of the time intervals than other subjects; the method comprising b) computing, for each subject of the population, a vector PP according to equation (I): ptk -[Pk 1, pk pk ni (I) wherein Pk1, Pk2, ...Pkn are the average values of the physiological parameter for the kth subject in the time intervals 1, 2, ... fz respectively; and c) computing, for the total population of subjects, a vector Pt according to equation (II): Ni N2 Nn 1 X 1 1 Pt = pk _Ip pkni ivi o, k 2 Nn v2 k=1 k=1 k=1 wherein N7, . . N"are the number of non-zero values of P1, pk2 Pk respectively for k = 1, 2, ... N.
- 9. A method according to claim 8, wherein the method further comprises associating components of the vector Pt with their corresponding time intervals, thereby to provide said time series of the physiological parameter for each subject over at least a part of a cycle of the cyclic time period.
- 10. A method according to claim 8 or 9, wherein the method further comprises the steps of: d) computing an average value PT of the physiological parameter for the population over the cyclic time period according to equation (Ill): PT = n Ni 1 1 r_I pki pk2,...k=1 k=1 k=1 Ni N2 Nn N2 1 1 (Ill); and e) computing a vector APi representing the time series of the physiological parameter by time interval according to equation (IV) N1 N" APe = - *Nn115kn-PT] k=1 -k=1 1 (IV) wherein the sub-cohort time series comprises the vector LIPt
- 11. A method according to any one of the preceding claims, wherein the time interval is 1 hour and the cyclic time period is a period of 24 hours.
- 12. A method according to any one of claims 1 to 10, wherein the time interval is 1 day and the cyclic time period is a period of 1 week.
- 13. A method according to any one of claims 1 to 10, wherein the time interval 1 month and the time period is a period of 1 year.
- 14. A method according to any preceding claim wherein the total number of subjects is at least 1,000, e.g. at least 10,000, e.g. at least 25,000, e.g. at least 50,000.
- 15. A method according to any preceding claim wherein the subjects are patients for example wherein the subjects are, or include, hospitalised patients.
- 16. A method according to claim 14 or claim 15, wherein the method further comprises a step of identifying a disorder to be treated from the output of the method.
- 17. A method according to claim 16 wherein the disorder is a cardiovascular disorder or a respiratory disorder.
- 18. A method according to any preceding claim wherein the physiological parameter is a parameter associated with a periodic physiological process.
- 19. A method according to any preceding claim wherein the physiological parameter is selected from blood pressure, peripheral oxygen saturation, respiration rate, pulse rate and body temperature.
- 20. A computer program product configured to perform the method of any preceding claim.
- 21. An apparatus comprising a processor and a database of time series of physiological parameter data, wherein the processor is configured to perform the method of any of claims 1 to 19.*
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1811060.1A GB2578271A (en) | 2018-07-05 | 2018-07-05 | Method and apparatus for designing a course of treatment |
GBGB1812051.9A GB201812051D0 (en) | 2018-07-05 | 2018-07-24 | Method and apparatus for designing a course of treatment |
PCT/GB2019/051913 WO2020008214A1 (en) | 2018-07-05 | 2019-07-05 | Method and apparatus for designing a course of treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1811060.1A GB2578271A (en) | 2018-07-05 | 2018-07-05 | Method and apparatus for designing a course of treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201811060D0 GB201811060D0 (en) | 2018-08-22 |
GB2578271A true GB2578271A (en) | 2020-05-06 |
Family
ID=63170825
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1811060.1A Withdrawn GB2578271A (en) | 2018-07-05 | 2018-07-05 | Method and apparatus for designing a course of treatment |
GBGB1812051.9A Ceased GB201812051D0 (en) | 2018-07-05 | 2018-07-24 | Method and apparatus for designing a course of treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1812051.9A Ceased GB201812051D0 (en) | 2018-07-05 | 2018-07-24 | Method and apparatus for designing a course of treatment |
Country Status (2)
Country | Link |
---|---|
GB (2) | GB2578271A (en) |
WO (1) | WO2020008214A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023223209A1 (en) * | 2022-05-16 | 2023-11-23 | Aktiia Sa | Apparatus for determining a cardiovascular risk score of a user |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111739604A (en) * | 2020-05-28 | 2020-10-02 | 思派健康产业投资有限公司 | Method for digging and implementing actual prescription for seeing doctor of slow patient group |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101806432B1 (en) * | 2008-03-26 | 2017-12-07 | 테라노스, 인코포레이티드 | Methods and systems for assessing clinical outcomes |
EP2862111A4 (en) * | 2012-06-18 | 2016-01-20 | Mayo Foundation | Determination of efficient time(s) for chemotherapy delivery |
-
2018
- 2018-07-05 GB GB1811060.1A patent/GB2578271A/en not_active Withdrawn
- 2018-07-24 GB GBGB1812051.9A patent/GB201812051D0/en not_active Ceased
-
2019
- 2019-07-05 WO PCT/GB2019/051913 patent/WO2020008214A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
None * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023223209A1 (en) * | 2022-05-16 | 2023-11-23 | Aktiia Sa | Apparatus for determining a cardiovascular risk score of a user |
Also Published As
Publication number | Publication date |
---|---|
GB201812051D0 (en) | 2018-09-05 |
GB201811060D0 (en) | 2018-08-22 |
WO2020008214A1 (en) | 2020-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Thombre et al. | Association between pre-pregnancy depression/anxiety symptoms and hypertensive disorders of pregnancy | |
Kendler | Demography of paranoid psychosis (delusional disorder): a review and comparison with schizophrenia and affective illness | |
Jönsson et al. | The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial | |
Doyle et al. | Associations between objective sleep and ambulatory blood pressure in a community sample | |
Lam et al. | Accurate prediction of duodenal-ulcer healing rate by discriminant analysis | |
Peter-Derex et al. | Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial | |
GB2578271A (en) | Method and apparatus for designing a course of treatment | |
Cohen et al. | Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study | |
Holland et al. | Racial/ethnic differences in control of cardiovascular risk factors among type 2 diabetes patients in an insured, ambulatory care population | |
Kim et al. | The Effect of Outpatient Cost Sharing on Health Care Utilization of the Elderly. | |
Miralles et al. | Experience with intravenous glucagon infusions as a treatment for resistant neonatal hypoglycemia | |
Hart et al. | The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink | |
JP2020031730A (en) | Data collection analyzer and data analysis method | |
Farsaei et al. | Glycemic control in the infectious diseases ward; role of clinical pharmacist interventions | |
Zak et al. | Sleep self-report and actigraphy measures in healthy midlife women: validity of the pittsburgh sleep quality index | |
Rudiansyah et al. | The Influence of Uric Acid Levels on Blood Pressure and Chronic Hypertension towards Hypertension Patient Proteinuria Levels (Overview of the Banjar Ethnic at the Cempaka Banjarmasin Health Center). | |
Bonda et al. | Circadian variations of interleukin 6 in coronary circulations of patients with myocardial infarction | |
Hirakawa et al. | Impact of gender on in-hospital mortality of patients with acute myocardial infarction undergoing percutaneous coronary intervention: an evaluation of the TAMIS-II data | |
Ogino et al. | Idiopathic bilateral adrenal haemorrhage related to acute adrenal insufficiency | |
Huang et al. | 7B. 09: blood pressure lowering efficacy of amlodipine and nifedipine-gits in ambulatory hypertension | |
Zevallos et al. | Gender Disparities in Puerto Ricans Hospitalized with an Initial Acute Myocardial Infarction: A Populationbased Perspective | |
Socchi et al. | Hemangiol in infantile haemangioma: A paediatric post‐marketing surveillance drug study | |
Zhang et al. | Self-reported sleep duration and pattern in old order amish and non-amish adults | |
WO2020082792A1 (en) | Method and device for monitoring medication of medical unit on basis of data processing | |
Wolf et al. | Blood pressure control in tertiary-care hypertensive patients during COVID-19 pandemic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |